Literature DB >> 26874886

Eribulin in soft-tissue sarcoma.

Robin J Young1, Penella J Woll2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26874886     DOI： 10.1016/S0140-6736(16)00162-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?

Authors:  Ravin Ratan; Shreyaskumar R Patel
Journal:  Curr Treat Options Oncol       Date:  2017-06

Review 2.  Advances in the treatment of soft tissue sarcoma: focus on eribulin.

Authors:  Panagiotis Koliou; Vasilios Karavasilis; Maria Theochari; Seth M Pollack; Robin L Jones; Khin Thway
Journal:  Cancer Manag Res       Date:  2018-02-01       Impact factor: 3.989

3.  Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?

Authors:  Sameer Rastogi; Vineet Gupta
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jan-Mar

Review 4.  Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.

Authors:  Colin Thomas; Sujana Movva
Journal:  Onco Targets Ther       Date:  2016-09-09       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.